|
Author | Year | Country | Exclusion criteria based on medication taking history | Patients with eye diseases | Healthy controls | Quality |
Number | NLR | Number | NLR |
Mean | SD | Mean | SD |
|
Keratoconus |
Karaca | 2014 | Turkey | Smoking habit, current anti-inflammatory therapies | 54 | 2.59 | 0.89 | 25 | 1.86 | 0.52 | Moderate |
Katipoglu | 2019 | Turkey | Anti-hyperlipidemic therapy or steroid use, or smoking and alcohol use | 31 | 2.30 | 0.80 | 31 | 1.70 | 0.60 | Low |
Bozkurt | 2020 | Turkey | ND | 35 | 2.01 | 0.53 | 30 | 1.97 | 0.41 | Moderate |
Elbeyli | 2021 | Turkey | Anti-hyperlipidemic therapy or steroid use, or smoking and alcohol use, current anti-inflammatory therapies | 42 | 2.50 | 0.80 | 42 | 1.70 | 0.30 | Low |
Oltutu | 2021 | Turkey | Smoker, and alcohol abuse, any medication that could affect blood parameters | 43 | 2.30 | 0.87 | 43 | 1.77 | 0.61 | Critical |
Reyhan | 2021 | Turkey | Currently receiving anti-inflammatory drugs, smoking, and alcohol use | 40 | 2.15 | 1.46 | 40 | 1.81 | 0.72 | Moderate |
Dry eye disease |
Sekeryap | 2016 | Turkey | Smoking, taking anti-inflammatory drugs | 33 | 2.80 | 1.40 | 32 | 1.60 | 0.70 | Low |
Celic | 2017 | Turkey | Smoking, receiving ocular/systemic drug | 78 | 1.84 | 0.50 | 60 | 2.60 | 1.20 | Moderate |
Ozcan | 2020 | Turkey | Smoking, systemic or ocular medications including topical steroids (the previous use during at least 3 months) and anti-inflammatory medications, that could affect the ocular surface of the eye and blood parameters | 47 | 2.26 | 0.55 | 47 | 1.81 | 0.55 | Moderate |
Meng | 2021 | China | Receiving hormone medication and systemic or tropical immunosuppressant during three months | 104 | 2.59 | 1.25 | 97 | 2.20 | 1.24 | Moderate |
Pterygium |
Akcam | 2019 | Turkey | Receiving topical/systemic drug, cigarette/alcohol using | 30 | 1.86 | 0.38 | 31 | 1.76 | 0.54 | Moderate |
Atilgan | 2019 | Turkey | Steroid use | 200 | 2.10 | 0.89 | 200 | 2.05 | 0.80 | Low |
Gokmen | 2019 | Turkey | Smoking, using steroid, or oral contraceptive drugs | 111 | 2.53 | 2.27 | 106 | 2.04 | 1.03 | Low |
Kilic 1 | 2019 | Turkey | Receiving antioxidant or anti-inflammatory medications or any topical or systemic drugs | 71 | 1.90 | 0.59 | 46 | 1.73 | 0.67 | Moderate |
Kurtul2 | 2019 | Turkey | Receiving immunosuppressive treatment | 61 | 1.85 | 0.82 | 55 | 2.72 | 0.79 | Low |
Kilic 2 | 2020 | Turkey | Past systemic medical therapy, smoking | 35 | 2.72 | 3.61 | 30 | 1.81 | 3.97 | Low |
Idiopathic epiretinal membrane |
Dilkaya | 2017 | Turkey | Any special drug use (e.g., corticosteroids iron preparations, vitamins, and chemotherapeutic agents) | 43 | 3.03 | 1.20 | 46 | 1.77 | 0.70 | Moderate |
Cubuk | 2020 | Turkey | Any drug use | 42 | 2.85 | 0.72 | 40 | 2.18 | 0.71 | Moderate |
Ulza | 2020 | Turkey | A history of systemic drug use | 57 | 2.10 | 0.90 | 51 | 1.64 | 0.46 | Low |
Demir | 2021 | Turkey | Receiving medications affecting whole blood parameters such as corticosteroid and iron and chemotherapeutic | 36 | 2.13 | 0.43 | 39 | 1.63 | 0.28 | Low |
Glaucoma |
Arikan | 2015 | Turkey | ND | 40 | 2.30 | 0.20 | 40 | 1.70 | 0.10 | Low |
Ozgonul1 | 2015 | Turkey | ND | 29 | 2.45 | 0.82 | 42 | 1.84 | 0.59 | Low |
Ozgonul2 | 2016 | Turkey | Any special drug use (e.g., corticosteroids, iron preparations, vitamins, and chemotherapeutic agents) | 84 | 2.33 | 0.90 | 80 | 1.98 | 0.73 | Moderate |
Li | 2017 | China | ND | 771 | 2.85 | 1.94 | 770 | 1.98 | 0.86 | Serious |
Kurtul 1 | 2018 | Turkey | ND | 14 | 2.19 | 0.78 | 43 | 1.56 | 0.58 | Moderate |
Atalay | 2019 | Turkey | Smoking | 28 | 1.82 | 0.68 | 27 | 2.21 | 0.84 | Moderate |
Tang | 2019 | China | Any special drug use (e.g., corticosteroids, iron preparations, vitamins, and chemotherapeutic agents) | 240 | 2.59 | 1.40 | 300 | 2.08 | 1.05 | Moderate |
Zhang | 2019 | China | ND | 59 | 2.07 | 0.88 | 84 | 2.73 | 1.30 | Low |
Demirtas | 2021 | Turkey | ND | 22 | 3.82 | 4.28 | 71 | 4.04 | 6.47 | Serious |
Karahan | 2021 | Turkey | ND | 200 | 5.40 | 9.28 | 100 | 3.00 | 4.91 | Moderate |
Bashir | 2022 | India | ND | 40 | 2.06 | 0.48 | 80 | 1.49 | 0.67 | Moderate |
Oh | 2022 | Korea | History of ocular drug use except cataracts | 41 | 1.94 | 0.60 | 100 | 1.70 | 0.56 | Moderate |
|